I can assure you all on the life of my dog and wife and son I did not see any Motley Fool piece on the name./ I woke up Sat and read about AI & Bio and I already know the name as you see I was on it from $6.
Another low blow by jealous Van. The man who can't. Hurrrrumph.
Hahahahaha.
Maybe you didn't.... but since you watch Cramer... one reader sent me an e-mail pointing out the fact that he had the CEO on Friday night.
Coincidence? Give us a break Stoney. Your "stock of the week was a pure Mad Money Monday morning momo play. Hey good on ya for following Jim. He is smart.
_______________________________
Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly
By Julie Coleman,CNBC • Published May 10, 2024 • Updated on May 10, 2024 at 8:47 pm
Source: Recursion Pharmaceuticals
Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly
" data-ellipsis="false">
- In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to create new drugs.
- Recursion Pharmaceuticals is a clinical-stage biotech company that received a $50 million investment from Nvidia last summer.
In a Friday interview with CNBC's
Jim Cramer,
Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to make the process of developing drugs faster and less expensive.
Recursion Pharmaceuticals is a clinical-stage biotech company that received a
$50 million investment from
Nvidia last summer. Gibson said Recursion is using this new technology to generate petabytes of data and then analyze it to "find new relationships across biology and chemistry" and create medicine, especially for rare diseases.
"I think with clinical trials, there's still going to be a few years to get through the clinical trial space," Gibson said. "But, to find the drug and get it into the clinic, I think we can shorten that from five or six years and hundreds of millions of dollars into, perhaps, one or two years and just $10 million or $20 million."
Recursion is currently developing a new drug to treat cerebral cavernous malformation, a neurovascular disease that Gibson said is not widely known but affects six times as many people in the U.S. than cystic fibrosis. Before Recursion's AI-focused approach, there wasn't a clear path toward making a drug to successfully tackle this disease, he said. The new treatment is almost done with its phase two trials.
Gibson said he thinks the use of this new technology to map biology will be common in the biopharma industry in five or 10 years.
______________________________
Good Cramer repost!
_________________________________________
As always.... at least my research is 10000% first-hand.
The savant flagged GME at $20.50 this AM out of the 4 AM gate. The real readers, that use actual money, are up huge. Unfortunately Yahoo Finance doesn't enable you to see these things. Maybe get a real trading package? Then you can play with the retail big-dogs. Other than that... your posts are pretty pathetic and totally not original. Plus they lack any sort of cerebral dissection. For example this:
A Trump win will be really good for this name.
SOC Sable Offshore Corp.- @$11.25
Long shot alert**$11.24-0.08 (-0.71%)
What kind of stupid statement is this and how is this any different than any energy stock? Where's the thought process to justify such a rookie statement? It's not in the chart. And it's not in the fundy's. The only thing it has is a low float, hard to borrow, and no options....
Whatever.
